Bergapten
Based on 5 publication(s) in Google Scholar
Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 484-20-8
- Formula: C12H8O4
- Molecular Weight:216.19
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
Medicine Food Homology Compound Library
HY-L055
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Mitochondria-Targeted Compound Library
HY-L089
-
Food-Sourced Compound Library
HY-L094
-
Tumorigenesis-Related Compound Library
HY-L100
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Tibetan Medicine Compound Library
HY-L191
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Chinese Baijiu Compound Library
HY-L241
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Bergapten
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
Cell Migration/Invasion Assay
-
Cell Imaging/Staining
-
WB
Biological Activity
CYP[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>20 μg/mL
Compound: 14
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 29975532] |
| HeLa | IC50 |
>20 μM
Compound: 5-MOP
|
The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark
The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark
|
[PMID: 10543884] |
| HeLa | IC50 |
16.3 μM
Compound: 5-MOP
|
The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)
The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)
|
[PMID: 10543884] |
| Hepatocyte | IC50 |
>100 μM
Compound: 15
|
Inhibitory activity against D-GalN-induced cytotoxicity in rat hepatocytes
Inhibitory activity against D-GalN-induced cytotoxicity in rat hepatocytes
|
[PMID: 9873511] |
| HepG2 | IC50 |
>20 μg/mL
Compound: 14
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 29975532] |
| HL-60 | IC50 |
>20 μM
Compound: 5-MOP
|
The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark
The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark
|
[PMID: 10543884] |
| HL-60 | IC50 |
3.35 μM
Compound: 5-MOP
|
The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)
The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)
|
[PMID: 10543884] |
| HSC-2 | CC50 |
0.72 mM
Compound: 24
|
Cytotoxicity against human HSC2 cells
Cytotoxicity against human HSC2 cells
|
[PMID: 11170668] |
| HT-1080 | IC50 |
0.9 μM
Compound: 5-MOP
|
Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line
Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line
|
[PMID: 12873520] |
| HT-1080 | IC50 |
1.8 μM
Compound: 5-MOP
|
Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line
Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line
|
[PMID: 12873520] |
| HT-1080 | IC50 |
8.5 μM
Compound: 5-MOP
|
Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line
Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line
|
[PMID: 12873520] |
| L929 | IC50 |
101 μM
Compound: 1, 5-MOP
|
Inhibition of Kv1.3 potassium channel expressed in mouse L929 cells by whole cell patch clamp
Inhibition of Kv1.3 potassium channel expressed in mouse L929 cells by whole cell patch clamp
|
[PMID: 19056148] |
| MDA-MB-231 | IC50 |
>20 μg/mL
Compound: 14
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 29975532] |
There is decreased N-acetyltransferase (NAT) activity in SC-M1 cells at concentrations of Bergapten (5-Methoxypsoralen, 5-MOP) from 0.05 mM to 25 mM, but no obvious dose-dependent effect is found between these doses (r=0.5687). In COLO 205 cells, there is decreased NAT activity at low doses of Bergapten (0.05 mM and 0.5 mM) and increased NAT activity at a high dose (50 mM). Bergapten induces a dosedependent effect in our experimental concentrations on COLO 205 cells (r=0.8912); a promotion effect at a higher dose (50 mM) and an inhibition effect at lower doses (0.05-0.5 mM), while the concentrations 5-25 mM has no significant difference compared with the control regimen[1]. Bergapten (5-Methoxypsoralen) exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Bergapten has also been shown to significantly inhibit the production of pro-inflammatory cytokines. Bergapten exhibits the ability to significantly inhibit RANKL-RANK signaling transduction, and to suppress the activation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways, thus protecting trabecular structure and decreasing osteoclastogenic differentiation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 484-20-8
-
Appearance Solid
-
Molecular Weight 216.19
-
Formula C12H8O4
-
Color White to off-white
-
SMILES
O=C1C=CC2=C(OC)C3=C(OC=C3)C=C2O1
-
Synonyms
5-Methoxypsoralen
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
2023 Sep;44(9):1867-1878. PMID: 37142684
Bergapten purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Sep;44(9):1867-1878. [Abstract]
Bergapten (BeG; 5, 10, 20 μM; 2 h) inhibits the expression of cleaved caspase-1 in BMDMs and J774A.1 cells.(5, 10 μM for J774A.1 cells, 20 μM for both)
-
PLoS Biol
2024 Jun 27;22(6):e3002672. PMID: 38935621 -
Oncol Lett
Network pharmacology and molecular docking reveal the mechanism of action of Bergapten against non‑small cell lung cancer. [Abstract]2024 Dec 4;29(2):87. PMID: 39677411
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
After 72 h of treatment with Bergapten (5-methoxypsoralen, 0-60 μM, 72 h), the viability of these cells was measured using the Cell Counting Kit-8 assay and the optimal drug concentration was determined.
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
Apoptosis levels was measured using flow cytometry after 72 h of treatment with Bergapten (5-methoxypsoralen, 30-50 μM, 72 h).
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
5-methoxypsoralen inhibits the migration of lung cancer cells. Representative images of wound healing assays using 40 or 50 µM Bergapten (5-methoxypsoralen) in NCI-H1299.
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
Representative images of NCI-H1975, NCI-H129 and NCI-H460 cells treated with 40 or 50 µM Bergapten (magnification, ×200).
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
Western blot analysis used to determine the expression of P-PI3K, PI3K, P-AKT and AKT proteins in three types of cells after treatment Bergapten.
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
RT-qPCR analysis determined the P16, P21, MMP12, IL6 and IL8 mRNA levels after treatment with Bergapten.
Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]
ELISA was used to detect the AKT activation levels of three cell lines after treatment with 5-methoxypsoralen, 5-methoxypsoralen + DMSO and Bergapten + SC79.
-
-
bioRxiv
An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]2024 Apr 3:2023.06.02.542933. PMID: 37333363
Solvent & Solubility
DMSO : 20 mg/mL (92.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1 mg/mL (4.63 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
The human colon adenocarcinoma cell line (COLO 205, from a 70-year-old male Caucasian) sre placed into 75-cm2 tissue culture flasks and grown in RPMI1640 medium, supplemented with 10% fetal bovine serum, containing penicillin and streptomycin (100 μg/mL) and 1 mM glutamine, at 37°C in a humidified atmosphere of 5% CO2 and 95% O2. The human stomach adenocarcinoma cell line are placed into 75-cm2 tissue culture flasks and grown in RPMI 1640 medium, supplemented with 10% fetal bovine serum, containing penicillin and streptomycin (100 μg/mL) and 1 mM glutamine, at 37°C in a humidified atmosphere of 5% CO2 and 95% O2. SC-M1 and COLO 205 cells are treated with different concentrations of Bergapten (0.05, 0.5, 5, 10, 25 and 50 mM) and incubated for 72 h for the dose-effect study of Bergapten on NAT activity. To determine the time-course effect of 0.5 mM Bergapten on NAT activity, the cells are incubated at 37AC and harvested at 12, 24, 48 and 72 h, respectively. Bergapten is dissolved in DMSO and the final concentration of vehicle is <0.1%. Only DMSO (solvent) is added for the control regimen[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[1]
Seventy-two male Sprague-Dawley (SD) rats, weighing approximately 200 g are used. A total of 72 rats are subjected to 3 different regimens, each regimen divided into 4 groups with 6 rats in each group. Gastric intubation is used for delivery of the test compounds into each animal. The first regimen received 1 mL Bergapten (dissolved in DMSO) at a dose of 0.5 mmol per Kg of body weight. Regimen 2, the control regimen, received only 1 mL solvent (DMSO), without any Bergapten. Regimen 3, the contrast regimen, received nothing at that time. Twenty-four h later, all of the rats from the 3 regimens received 1mL AF (dissolved in DMSO) at a dose of 0.3 mmol per Kg of body weight. The groups are divided by different collecting time: 12, 24, 48 and 72 h after AF administration, and then the animals are transferred to individual metabolism cages. The stomachs and the colons of the rats from each regimen are collected and are immediately extracted with ethyl acetate/methanol (95:5). The solvent is evaporated and the residue redissolved in methanol and assayed for AF and AAF by HPLC.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee YM, et al. Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines. In Vivo. 2005 Nov-Dec;19(6):1061-9. [Content Brief]
[2]. Li XJ, et al. Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Int J Mol Med. 2016 Dec;38(6):1661-1672. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.6256 mL | 23.1278 mL | 46.2556 mL | 115.6390 mL |
| 5 mM | 0.9251 mL | 4.6256 mL | 9.2511 mL | 23.1278 mL | |
| 10 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL | 11.5639 mL | |
| 15 mM | 0.3084 mL | 1.5419 mL | 3.0837 mL | 7.7093 mL | |
| 20 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL | 5.7820 mL | |
| 25 mM | 0.1850 mL | 0.9251 mL | 1.8502 mL | 4.6256 mL | |
| 30 mM | 0.1542 mL | 0.7709 mL | 1.5419 mL | 3.8546 mL | |
| 40 mM | 0.1156 mL | 0.5782 mL | 1.1564 mL | 2.8910 mL | |
| 50 mM | 0.0925 mL | 0.4626 mL | 0.9251 mL | 2.3128 mL | |
| 60 mM | 0.0771 mL | 0.3855 mL | 0.7709 mL | 1.9273 mL | |
| 80 mM | 0.0578 mL | 0.2891 mL | 0.5782 mL | 1.4455 mL |
Powered by Bioz